{"id":"NCT00319111","sponsor":"Actelion","briefTitle":"Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","officialTitle":"Long-term Open-label Extension Study in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Who Completed Protocol AC-052-366 (BENEFIT, NCT00313222)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01","primaryCompletion":"2009-02","completion":"2009-04","firstPosted":"2006-04-27","resultsPosted":"2012-12-31","lastUpdate":"2025-02-04"},"enrollment":151,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Hypertension"],"interventions":[{"type":"DRUG","name":"bosentan","otherNames":[]}],"arms":[{"label":"Bosentan","type":"EXPERIMENTAL"}],"summary":"The present trial investigates the long-term safety, tolerability and efficacy of bosentan in patients with inoperable CTEPH.","primaryOutcome":{"measure":"Change From Baseline to All Assessed Time Points in 6-minute Walk Test (6MWT) Distance","timeFrame":"Until discontinuation of study drug, up to 3.3 years","effectByArm":[{"arm":"Bosentan","deltaMin":8.4,"sd":66.4}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":151},"commonTop":["HEPATIC ENZYME INCREASED","LIVER FUNCTION TEST ABNORMAL","ANOREXIA","ASPARTATE AMINOTRANSFERASE INCREASED","DYSPEPSIA"]}}